Canaccord Genuity Reiterates Buy on Verona Pharma, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash has reiterated a 'Buy' rating on Verona Pharma (NASDAQ:VRNA) and maintained a price target of $35.
September 01, 2023 | 2:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verona Pharma's stock rating has been reiterated as 'Buy' by Canaccord Genuity with a maintained price target of $35.
The reiteration of a 'Buy' rating by Canaccord Genuity indicates a positive outlook for Verona Pharma. The maintained price target of $35 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100